Diabetic Macular Edema
Conditions
Keywords
DME, Endothelial dysfunction blocker
Brief summary
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
Interventions
DRUGCU06-1004, Single dose
Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊ ＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5
DRUGCU06-1004, Multiple doses
Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule ＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD
DRUGPlacebo
Placebo matched to CU06-1004, oral capsule
Sponsors
KCRN Research, LLC
Curacle Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A Single Ascending Dose(SAD) study with 7 Cohorts including 1 Cohorts for Food effect (FE) assessment with 8 subjects each (6 active and 2 placebo) and A Multiple Ascending Dose(MAD) study with 3 Cohorts with 8 subjects each (6 active and 2 placebo).
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy, adult, male or female (of non-childbearing potential only), 19-55 years of age, inclusive, at screening. 2. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening. 3. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting. 4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. 5. Female must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing: * hysteroscopic sterilization; * bilateral tubal ligation or bilateral salpingectomy; * hysterectomy; * bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status. 6. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomized less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomized male). 7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing. 8. Able to swallow multiple capsules. 9. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.
Exclusion criteria
1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study. 2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee. 3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study. 4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing. 5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds. 6. Female subjects of childbearing potential. 7. Female subjects with a positive pregnancy test at screening or first check-in or who are lactating. 8. Positive urine drug or alcohol results at screening or first check-in. 9. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV). 10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, at screening. 11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening. 12. QTcF interval is \>460 msec (males) or \>470 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at screening. 13. Unable to refrain from or anticipates the use of: * Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements (especially sulforaphane-containing supplement) beginning 14 days prior to the first dosing and throughout the study. After randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee. * Food and beverages containing xanthines/caffeine for 24 hours prior to the first dosing (small amounts of caffeine derived from normal foodstuffs e.g.,250 mL/8 oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this restriction). * Food and beverages containing alcohol for 48 hours prior to the first dosing. * Food and beverages containing grapefruit/Seville orange for 14 days prior to the first dosing. * Food and beverages containing vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meats for 14 days prior to the first dosing. 14. Has received COVID-19 vaccine within 30 days of first dosing and until the end of the study. 15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study. 16. Is lactose intolerant (FE cohort only). 17. Donation of blood or significant blood loss within 56 days prior to the first dosing. 18. Plasma donation within 7 days prior to the first dosing. 19. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the first dose of study drug in the current study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number and severity of treatment emergent adverse events (TEAEs) | From the date of first dose through 7 days after the last dose | To assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to reach maximum plasma concentration (Tmax) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess Tmax of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Area under the concentration-time curve (AUC) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess AUC of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Terminal elimination rate constant (Kel) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess Kel of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Terminal elimination half-life (t½) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess t½ of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Maximum plasma concentration (Cmax) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess Cmax of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Area under the concentration-time curve (AUC) under fed conditions | Day 1 through Day 4 (SAD) | To assess AUC of single oral dose under fed conditions |
| Amount of unchanged drug excreted in the urine collection (Ae) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess Ae of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Renal Clearance (CLR) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess CLR of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Fraction of drug excreted unchanged in urine (Fe) | Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD) | To assess Fe of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects |
| Maximum plasma concentration (Cmax) under fed conditions | Day 1 through Day 4 (SAD) | To assess Cmax of single oral dose under fed conditions |
Countries
United States
Outcome results
None listed